Cancer Research 2010 AACR Elections  2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 10121, December 15, 2008. doi: 10.1158/0008-5472.CAN-08-2121
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hillion, J.
Right arrow Articles by Resar, L. M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hillion, J.
Right arrow Articles by Resar, L. M. S.

Cell, Tumor, and Stem Cell Biology

The High-Mobility Group A1a/Signal Transducer and Activator of Transcription-3 Axis: An Achilles Heel for Hematopoietic Malignancies?

Joelle Hillion1,2, Surajit Dhara1,2,3,4, Takita Felder Sumter1,2,3, Mita Mukherjee1,2,3, Francescopaolo Di Cello1,2, Amy Belton1,2, James Turkson6,7, Souyma Jaganathan6,7, Linzhao Cheng4, Zhaohui Ye4, Richard Jove8,9, Peter Aplan10, Ying-Wei Lin10, Kelsey Wertzler11, Ray Reeves11, Ossama Elbahlouh1,2,3, Jeanne Kowalski5, Raka Bhattacharya1,2,3 and Linda M. S. Resar1,2,3,4

1 Hematology Division and 2 Departments of Medicine, 3 Pediatrics, 4 Oncology, and 5 Biostatistics, The Johns Hopkins University School of Medicine, Baltimore, Maryland; 6 BioMolecular Science Center and 7 Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, Florida; 8 Experimental Therapeutics Program, City of Hope Comprehensive Cancer Center and 9 Division of Molecular Medicine, Beckman Research Institute, City of Hope, Duarte, California; 10 National Cancer Institute, Center for Cancer Research, Genetics Branch, Bethesda, Maryland; and 11 Washington State University, Pullman, Washington

Requests for reprints: Linda M.S. Resar, The Johns Hopkins University School of Medicine, Ross Research Building, Room 1025, 720 Rutland Avenue, Baltimore, MD 21205. Phone: 410-614-0712; Fax: 410-955-0185; E-mail: lresar{at}jhmi.edu.

Key Words: HMGA1 • STAT3 • target gene • oncogene • hematopoietic malignancy

Although HMGA1 (high-mobility group A1; formerly HMG-I/Y) is an oncogene that is widely overexpressed in aggressive cancers, the molecular mechanisms underlying transformation by HMGA1 are only beginning to emerge. HMGA1 encodes the HMGA1a and HMGA1b protein isoforms, which function in regulating gene expression. To determine how HMGA1 leads to neoplastic transformation, we looked for genes regulated by HMGA1 using gene expression profile analysis. Here, we show that the STAT3 gene, which encodes the signaling molecule signal transducer and activator of transcription 3 (STAT3), is a critical downstream target of HMGA1a. STAT3 mRNA and protein are up-regulated in fibroblasts overexpressing HMGA1a and activated STAT3 recapitulates the transforming activity of HMGA1a in fibroblasts. HMGA1a also binds directly to a conserved region of the STAT3 promoter in vivo in human leukemia cells by chromatin immunoprecipitation and activates transcription of the STAT3 promoter in transfection experiments. To determine if this pathway contributes to HMGA1-mediated transformation, we investigated STAT3 expression in our HMGA1a transgenic mice, all of which developed aggressive lymphoid malignancy. STAT3 expression was increased in the leukemia cells from our transgenics but not in control cells. Blocking STAT3 function induced apoptosis in the transgenic leukemia cells but not in controls. In primary human leukemia samples, there was a positive correlation between HMGA1a and STAT3 mRNA. Moreover, blocking STAT3 function in human leukemia or lymphoma cells led to decreased cellular motility and foci formation. Our results show that the HMGA1a–STAT3 axis is a potential Achilles heel that could be exploited therapeutically in hematopoietic and other malignancies overexpressing HMGA1a. [Cancer Res 2008;68(24):10121–7]




This article has been cited by other articles:


Home page
Cancer Res.Home page
L. M.S. Resar
The High Mobility Group A1 Gene: Transforming Inflammatory Signals into Cancer?
Cancer Res., January 15, 2010; 70(2): 436 - 439.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
J. Hillion, L. J. Wood, M. Mukherjee, R. Bhattacharya, F. Di Cello, J. Kowalski, O. Elbahloul, J. Segal, J. Poirier, C. M. Rudin, et al.
Upregulation of MMP-2 by HMGA1 Promotes Transformation in Undifferentiated, Large-Cell Lung Cancer
Mol. Cancer Res., November 1, 2009; 7(11): 1803 - 1812.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
L. Mao, K. J. Wertzler, S. C. Maloney, Z. Wang, N. S. Magnuson, and R. Reeves
HMGA1 Levels Influence Mitochondrial Function and Mitochondrial DNA Repair Efficiency
Mol. Cell. Biol., October 15, 2009; 29(20): 5426 - 5440.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.